This conceptual review examines the ideal multistep synthesis from the perspective of nature. We suggest that besides step-and redox economies, one other key to efficiency is steady state processing with intermediates that are immediately transformed to the next intermediate when formed. We discuss four of nature's strategies (multicatalysis, domino reactions, iteration and compartmentation) that commonly proceed via short-lived intermediates and show that these strategies are also part of the chemist's portfolio. We particularly focus on compartmentation which in nature is found microscopically within cells (organelles) and between cells and on a molecular level on multiprotein scaffolds (e.g. in polyketide synthases) and demonstrate how compartmentation is manifested in modern multistep flow synthesis.
Introduction
What is a perfect multistep synthesis? This is a key issue which has received much attention recently, despite the fact that as early as 1975 Hendrickson had already provided a denition for an "ideal synthesis". According to him it is one which: .creates a complex molecule. in a sequence of only construction reactions involving no intermediary refunctionalisations, and leading directly to the target, not only its skeleton but also its correctly placed functionality.
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Many years later this general statement was complemented with ideas such as, atom, 2 step, 3 and redox-economy 4 that serve as standards by which the efficiency of chemical reactions and syntheses can be measured. 5 However, some of these concepts are restricted to individual chemical transformations and the underlying mechanisms to achieve selectivity. The Baran group has discussed and provided criteria that allow for comparison and even quantication of multistep synthesis. They cited three specic criteria: (a) overall yield, (b) step count and (c) percent ideality. 5 The authors also acknowledge that the % ideality should be used with caution and is more of a simple tool than a true overarching measure of efficiency. Today, these straightforward concepts are generally accepted within the synthetic community as they reect an important step toward striving for improved efficiency.
In several aspects, nature can be seen as an ideal synthetic chemist. Understanding the biosynthesis of a natural product is oen a productive starting point for the design of highly efficient, biomimetic total syntheses.
6 Still, chemists have yet to achieve the same exquisite levels of selectivity, particularly, chemoselectivity, in the design of multistep processes. However, analysis of biosynthetic pathways reveals that atom-, redox-and step economies are not always well fullled in nature although from the synthetic chemist's point of view biosyntheses of complex natural products are regarded to be highly efficient. This may sound like a contradiction.
Herein, we discuss four fundamental strategies that are shared in both synthetic chemistry and nature, in so doing, we wish to shed light on this seeming contradiction. Based on these strategies, it is interesting to see the interplay between the chemist and nature, where the chemist can be seen to borrow from nature and in certain cases even improve on nature's design. The hope of this highlight is to discuss these fundamental strategies in a broad context taking examples from biosynthesis and the state of the art in organic synthesis and presenting them side by side. To clarify the scope of this review is not about biomimetic synthesis and we have deliberately not chosen biomimetic chemical syntheses as this has been extensively reviewed elsewhere.
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In this unique setting we hope to inspire the synthetic chemist to think more on natural systems for inspiration. Too oen does the chemist draw a line between themselves and biologists, we hope to encourage a blurring of the lines. 7 
Step-and redox-economies in nature
In order to discuss the issue of step-economy in nature let us rst take a look at erythronolide A (1a). It is composed of a macrolactone ring that is biosynthesised by a polyketide synthase type 1 (PKS). Starting from propionyl-CoA 14 transformations (additional four steps have to be added, if one starts counting from acetyl-CoA, additional six steps if transacylation steps from AT to ACP on the PKS are included, and additional seven steps if the activation and loading of the starter and elongation units are included) occur in a linear fashion to yield 6-deoxyerythronolide B (1b). Aer this, ve additional biosynthetic tailoring steps fashion erythromycin A (2).
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So far, the rst and only total synthesis of 2 was reported by Woodward and coworkers in 1981. This formidable synthesis was achieved in 69 (batch) steps (61 in the longest linear sequence) from commercially available starting materials. However, the bioproduction of erythromycin A (2) rough estimate on the productivity in S. erythraea is possible. About 0.18-0.53% of the glucose fed ends up in erythromycin (2).
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While this yield may not seem very impressive it is still signi-cantly larger than the yield in the only total synthesis (less than 0.02%). One gram of (dry) biomass produces up to 0.75 mg h À1 of 2 starting from 0.21 g h À1 glucose.
The biosynthesis 13 of the pseudomonic acids, secondary metabolites originally isolated from Pseudomonas uorescens NCIMB 10586, is an illustrative showcase for poor step-and redox-economy in nature (Scheme 2). A tetrahydropyran ring is a central structural element of the pseudomonic acids and starting from the advanced biosynthetic intermediate 3 it is formed by a six step sequence that includes two oxidations, two reductions an epoxide ring-opening and a dehydration to yield pyran 4. A chemist would likely suggest a single step alcohol addition onto the olenic double bond in an anti-Markovnikov fashion. Despite these facts pseudomonic acids are produced by fermentation and are used under the name mupirocin against staphylococci and non-enteric streptococci.
One may speculate why many biosyntheses are linear and rather long, occasionally with poor redox-economy. From a chemists perspective the repertoire of reactions and building blocks nature can rely on is rather small. Additionally, it has been hesitant to develop new biosynthetic pathways. nature rather sticks to established multistep processes. Oen iteration and the addition of "decorating" or "tailoring" steps lead to ever longer linear biosyntheses. From an evolutionary point of view long biosyntheses originate from genes that were incorporated into biosynthetic gene clusters and became nally operative, when the new metabolite provided improved survival for the producing organism.
14 Unlike most chemical syntheses, biosyntheses are not batch but steady state processes in which intermediates are directly processed as they are formed. We believe that this fact is important to approach the topic of a perfect multistep synthesis from nature's perspective. Therefore, we shall begin with a "Gedanken-experiment" of a conventional multistep batch synthesis in order to be able to mirror it with nature's multistep processes before we discuss the four synthetic strategies.
The flaw of multistep batch synthesis is its batch character
Synthetic chemists commonly conduct multistep processes under batch conditions in which intermediates are formed in equimolar amounts and if necessary need to be isolated and/or further puried. Practically, batch mode synthesis is time consuming and uneconomical and here atom, step and redoxeconomies do matter.
In this context, the patented synthesis of olanzapine (7) is illustrative. 15 Olanzapine is commercialised under the name ZYPREXA® and was among the top 20 best selling drugs worldwide in 2011. ZYPREXA® is an atypical neurolepticum and is used for the treatment of bipolar disorders and schizophrenia.
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It is known to exert antagonistic activity towards the dopamine receptor type 4 (D 4 -receptor) and the serotonin receptor type 2 (5-HT 2 -receptor).
17 The patent 15 describes a four step batch protocol starting from 1-uoro-2-nitrobenzene (5) and 2-amino-5-methylthiophene-3-carbonitrile (6). Assuming the preparation of 1 kg (3.2 mol) of 7 with quantitative yield for each step (Fig. 1) . This would require about 0.5 kg of starting materials 5 and 6, and more than 0.8 kg of three intermediates are formed that need to be isolated. As a consequence multistep reaction sequences should ideally avoid work-up and isolation of intermediates.
At rst glance the bioproduction of complex natural products such as erythromycin A (2) may look like a true batch protocol (Fig. 2) . D-Glucose is the starting material, Saccharopolyspora erythrea acts as the "catalytic" system 18 and the fermenter resembles the ask or the reactor. Harvesting the bioreactor, yields the antibiotic 2, still being used in the clinic.
The gross simplication depicted in Fig. 2 treats Saccharopolyspora erythrea as a black box or a batch reactor. Using the tools of molecular biology and biochemistry we can pry into these multicatalytic biosystems. In fact, the biosynthesis of erythromycin A (2) is a highly orchestrated multistep and rather linear steady state process, catalyzed by enzymes, many being part of a catalytic megacomplex, the polyketide synthase (PKS, vide infra). In contrast to the multistep batch process depicted in Fig. 1 , these catalytic architectures circumvent the stoichiometric formation of intermediates.
Primary metabolism "feeds" the biosynthetic pathways of secondary metabolite production and is organised in a complex network of enzymatic transformations and routes. A biosynthetic intermediate is oen generated from different sources and the intermediate can be the starting point for different biosynthetic routes as exemplied in Fig. 3 . In most cases, building blocks A are activated carboxylic acids such as acetylor propionyl-CoA, aminoacyl phosphates or alkyl diphosphates.
Oen tailoring transformations such as acylations, alkylations or glycosylations implement further "decoration" into the backbone (e.g. I 4 / B, Fig. 3 ). Intermediates I are difficult to detect or to track, so that rst insights into biosynthetic pathways came from the isolation of biosynthetic end product B, while manifestation of intermediates I was necessary to provide a detailed description of the pathways. 19 These biosyntheses either rely on a cocktail of individual enzymes (e.g. in terpene biosynthesis) 20 or are based on megaenzyme complexes such as the polyketide synthases that are e.g. part of erythromycin (2) biosynthesis, or non-ribosomal peptide synthases (NRPS). In both cases the templating property of PKS and NRPS guarantee spatial separation or compartmentation of each step (see also chapter 4.4). Now that we have provided an overview of secondary metabolite biosynthesis, with an emphasis on polyketides biosynthesis, we will go on to discuss four strategies that nature has developed in order to allow for efficient multistep synthesis with seeming disregard to the chemists notion of step count and atom economy. Typically, the strategies are based on steady state processes and are (a) multicatalysis, (b) domino/cascade reactions, (c) iteration and (d) compartmentation. We discuss compartmentation in greater detail 21,22 as this aspect can hardly be found in the literature yet.
3 Overall, these four strategies add to those justied and oen discussed arguments that are based on protecting group chemistry and the high chemo-, regio-and chemoselectivities of biocatalysts. are a typical example for a multicatalytic biosynthetic pathway (Scheme 3). Two distinct biosynthetic pathways, namely the mevalonate and the deoxyxylulose route, 24 provide nature's isoprene analogues isopentenyl pyrophosphate [IPP (8)] and dimethylallyl pyrophosphate [DMAPP (9)]. The former pathway utilises six enzymes to reach IPP starting from SCoA activated acetic acid, while the latter route requires seven enzymes starting from pyruvate (12) and glycerinaldehyde-3-phosphate (13). Then, an iterative process provides geranyl pyrophosphate [GPP (10)], farnesyl pyrophosphate [FPP (11)], geranyl geranyl pyrophosphate and squalene. Each of these advanced intermediate building blocks represents one of the terpene classes (e.g. mono-, di-, sesqui-, tri-and tetraterpenes).
Multicatalytic reactions and sequences have also emerged in organic synthesis. These systems could be purely based on biocatalysts and synthetic catalysts or on biocatalyst/synthetic catalyst combinations. 25 Within the category of synthetic catalysts further subdivisions can be made based upon whether the catalyst is an organocatalyst or based on inorganic/organometallic catalysts (Fig. 4) .
The combination of multiple catalysts has several benets such as reduced waste, reduced overall time to realise multistep syntheses, the ability to control unstable intermediates and the ability to generate molecular complexity from simple precursors. However, certain points must be taken into account, such as the compatibility of starting materials/intermediates and catalysts with each other and with the reaction conditions (temperature, solvent, pressure etc.). Additionally, the relative rates of the individual processes, and the selectivity of the individual catalysts must be considered, such that reactions occur in a denite sequence on precisely the intermediate which one intends. Despite many parameters needing to be controlled", researchers have begun to uncover reactions and strategies which already led to several impressive examples.
An exciting new eld in the arena of multicatalysis is the use of several metal catalysts that operate orthogonally in one pot and provide highly complex molecular architectures from simple precursors. Jeong and co-workers 26 reported one of the rst examples of a multicatalytic palladium/rhodium system with multiple C-C bonds being formed (Scheme 4). Initially, a palladium-catalyzed allylation between malonyl derivative 14 and allyl acetate 15 takes place to furnish intermediate 17. This intermediate enters a second catalytic cycle where rhodium triggers a Pauson-Khand type reaction (PKR). Via intermediates 18 and 19 the bicyclic ring system 16 is generated in excellent yield. The authors found that the chosen rhodium precatalyst is critical to the success of the multicatalytic cascade. This example demonstrates the multitude of opportunities chemists have compared to nature when developing multistep sequences, as there are no analogous catalytic reactions known in nature.
Several examples of cooperative utilisation of transition metal catalysts, organocatalysts and even enzymes in one-pot have appeared in the literature. Jørgensen et al. showed that proline-derivative 22 and a p-Lewis acid based on gold or copper, can affect the reaction of propargyl malononitrile 21 with a,b-unsaturated aldehydes 20, to furnish highly enantioenriched cyclopentene carbaldehydes 23 (Scheme 5).
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Initially, the organocatalyst is responsible for iminium formation and directs highly selective 1,4-addition (intermediates 24 and 25). Then, the p-Lewis acid takes over (intermediate 26) disposing the alkyne toward intramolecular 5-exo-dig cyclisation to provide chiral cyclopentene carbaldehydes (intermediates 27 and 28). From control experiments it became evident that during transformation of 26 to 27 the two catalysts operate cooperatively.
As early as 2002 a multicatalytic system was reported that utilises an enzyme, an organocatalyst and a metal catalyst in water as the solvent in one-pot (Scheme 6). 28 The conversion of methyl b-D-galactoside (29) to methyl 4-deoxy-6-aldehydo-b-Dgalactoside (30) was initiated by the action of D-galactose oxidase that affects the oxidation at C-6. The resulting aldehyde (intermediate 31), in equilibrium with its hydrate, was warmed up and L-proline promoted dehydration to form the corresponding enal (intermediate 32). Finally, hydrogenation over palladium on charcoal gave the deoxygenated hexoside 30 in excellent yield. This process proceeded without purication or isolation of intermediates, only reagents are added and conditions are altered. Remarkably, this process does not require protection of hydroxyl groups and it demonstrates the power of multicatalysis in multistep processes.
Strategy 2: domino reactions
Domino or cascade reactions have emerged as an important tool for the organic chemist and over the past 20 years there has been a great deal of research in this area and a wealth of new processes have become available. As dened by Tietze, a domino reaction is a process whereby a starting material passes through two or more intermediates on its way to the nal product, in a sequential manner, where functionality generated in the rst step allows for further transformations to take place. 29 The whole process occurs under the same reaction conditions and commonly all components are present from the very beginning (Fig. 5) .
Nature also relies on this concept and in this context terpene cyclases are excellent examples. 30 These enzymes have the ability to control the reactivity of intermediate carbocations of a domino sequence that results in the large number of known oligocyclic terpenes. During cyclisation the ring sizes and the conguration of stereogenic centers formed are dictated by the dened folding of the linear pyrophosphate precursor and governed by stereoelectronic effects in the enzyme active site, where "special" conformations can be stabilised. Commonly, the domino sequence is initiated by formation of a 3,3-disubstituted allyl cation which reacts intramolecularly with one of the trisubstituted alkene moieties of the substrate. A new carbocation is formed which commonly has three options: (a) internal or external trapping of a nucleophile, (b) deprotonation and formation of an alkene or (c) Wagner-Meerwein rearrangement and formation of a new carbocation (Fig. 5 ).
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The taxadiene synthase that operates in the biosynthesis of the yew tree (Taxus brevifolia) metabolite paclitaxel (35, TAXOL®) is an illustrative example. Paclitaxel inhibits microtubule depolymerisation 32 and commercially is one of the most successful anti-cancer compounds. This diterperne is based on a 6-8-6 tricyclic carbon backbone which is formed from geranylgeranyl pyrophosphate (33) in an enzyme-catalyzed domino reaction (Scheme 7). The cascade proceeds through several cationic intermediates I-III formed either by p-solvolysis, elimination or H-shis. A series of tailoring oxidations and esterications provide paclitaxel via baccatin III (34) . Within this biosynthesis, another remarkable domino sequence occurs during the tailoring phase of the taxane backbone to form the oxetane ring as depicted in Scheme 8.
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Cationic intermediates also drive iminium biosyntheses of alkaloids. Anionic species govern cascade sequences in polyether and ladder polyether biosyntheses as studied in detail for monensin. 34 Radical cascade reactions are not very widespread in nature. Oen these sequences are short and represent rearrangements commonly initiated by S-adenosyl methionin or by vitamin B 12 .
In a similar fashion chemists have utilised this concept of creating reactive intermediates based on carbocations, carbanions and C-centered radicals to build up several carbocyclic systems in one step.
An impressive example was disclosed by the Kilburn group,
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in which SmI 2 is used to reductively initiate a radical cascade of cyclisation-ring expansion-cyclisation via proposed intermediates 39-41 starting from cyclopropyl ketone 36. The use of HMPA is supposed to inuence the respective size of the coordinating samarium, thus stabilizing either intermediate I or II and hence controlling the relative stereochemistry of the product 37 and 38, respectively (Scheme 9). Although this domino reaction differs from terpene cyclasepromoted biosyntheses in that radicals instead of carbocations are the highly reactive intermediates, the underlying principles of domino reactions are alike. In the case of terpene cyclases the resulting stereochemistry is controlled by the asymmetric environment provided by the biocatalyst which exerts a dened conformation of the substrate. In the Kilburn example the starting material prefolds to a preferred conformer in solution, which can further be adjusted by choice of additional ligands on the samarium species.
This concept of creating a reactive intermediate which initiates a second very different reaction is rather common in transition metal catalysis. Recently, Tietze et al. published an example of a palladium catalyzed carbopalladation-C-H activation sequence (Scheme 10). 36 The reaction starts with Pd insertion into the carbon halogen bond followed by a 6-exo-dig cyclisation through carbometalation of the triple bond to furnish intermediate 44. The close proximity of the aryl group to the metal center initiates a C-H insertion of the palladium, resulting in the formation of the product 43 aer reductive elimination.
Strategy 3: iterative reactions
Iteration of steps as was discussed for the acyclic terpene pyrophosphates in Scheme 3, is a third concept how nature simplies biosynthetic processes.
Indeed, modularity is widespread in nature and can also be found in polypeptides, oligonucleotides and oligosaccharides, indeed most natural small-molecules are biosynthesised via iterative coupling reactions. In contrast to bacterial type 1 polyketide synthases that are arranged in a complex modular fashion (see also erythromycin PKS in chapter 4.4), fungal polyketide synthases use only a simplied enzymatic machinery that is still able to create large and complex molecular architectures. The key for understanding these fungal PKS modules is their ability to operate iteratively. 37 The exact mechanism of chain extension is largely unknown but their impressive iterative power is demonstrated in the reconstitution of the PKS of dihydromonacolin (46) . Compound 46 is a precursor of the hypolipidemic drug lovastatin 47 that is produced by Aspergillus terreus (Scheme 11).
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The catalytic domains are organised in the one multifunctional (LovB) and one monofunctional protein (LovC) that are responsible for the biosynthesis of 46. The individual enzymatic units within the domains are iteratively used up to eight times before release from the PKS.
38b The nal product 46 is formed aer a bioprocess consisting of seven iterations that only differ in the number of enzymatic units operating and the length of the carbon backbone of the ACP-bound intermediates. As a result only seven different enzymes are required to perform 21 reactions. At rst glance, the iterative process is not revealed in the structure of 46. But the structural complexity is further increased because of an intervening intramolecular Diels-Alder cycloaddition, which most likely proceeds in a spontaneous manner (Scheme 11).
Polyketides of type II are formed by even more simplied PKS variants which are composed of only KS a , KS b and ACP domains. 39 The KS a and the ACP domains work in an iterative sense, while KS b , also known as chain initiation factor, programming the nal length of the polyketide chain as KS b converts malonyl ACP to acetyl CoA to form the starter unit. Optionally, other domains can be present such as ketoreductases (KR), cyclases (CYC) and aromatases (ARO). Interestingly, these enzymes are not an element of the PKS but are associated with it and serve to modify the linear polyketide chain.
In Scheme 12 the iterative process for the biosynthesis of decaketides is summarised. Starting from one propionyl-CoA and nine malonyl-CoA extender units, nine iterative loops yield the intermediate polyketone which can be further processed to a variety of different carbon skeletons that are subsequently processed to anthracycline antibiotics such as daunorubicin (50) . Although the factors and proteins governing and controlling the number of iterations are not fully understood yet, it is discussed that folding of the substrate in the enzyme pocket is crucial and once a certain chain length is reached the iterative process stops. Noteworthy, the biosynthesis nicely demonstrates the high reactivity of intermediate 48 -a lack of the cyclase results in spontaneous cyclisation to other products such as 51 and 52. 39, 40 Iterative sequences have also been developed by chemists. This strategy provides complexity in a modular fashion from simple precursors. In analogy to iteration by fungal PKS or type II PKS, the Yamamoto group found that supersilyl enol ethers 53 Scheme 13 Iterative aldol reactions and proposed transition state for syn-product.
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can be utilised for iterative aldol processes with aldehydes to yield aldol products 54 with high syn-selectivity (Scheme 13).
Although a new aldehyde is formed, the second aldol reaction is retarded due to the large size of the supersilyl group. Additives such as PhI facilitated oligoaldol processes. For example one triple aldol reaction provided polyketide-type triol 57 from silyl enol ether 56 (R ¼ H) and 3-nitro propanal 55 (Scheme 14). It was postulated that organoiodides react with (Me 3 Si) 3 SiNTf 2 to furnish a cationic, sterically less congested complex of the type RI-Si(SiMe 3 ) 3 + NTf 2 À . The iterative process was successfully applied 43 in the synthesis of the polymethoxy-1-alkene 61 that was, among other metabolites, isolated from the polytoxin producing blue-green algae Tolypothrix conglutinate. Here, this aldol reaction proceeds three times before being terminated due to the steric congestion present in the product. 1-Iodo-2-phenylacetylene serves as a mediator. 44 The fact that structural parameters such as bulkiness lead to termination of the iterative cycle also likely play a role in type 2 PKS biosynthesis as discussed above.
The group of Martin Burke developed a powerful methodology based upon iterative cross-coupling reactions of bifunctional MIDA-boronates (Scheme 15). In principal, the polarity of elements n or i can be exibly chosen such that selective crosscoupling occurs in a stereoretentive sense to give the adduct n + i, deprotection and activation of the boronate then takes place aer which time additional steps may invert the polarity of the substrate. Possible options are the conversion of the vinyl boronate into a vinyl halide or the formation of pinacol boronates. This cycle can be repeated several times to access fragments in stereochemically pure form bearing appropriate functionality for further reactions. The different principal options of this new methodology becomes evident when studying the total syntheses of the polyenes synechoxanthin (67) (Scheme 16).
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The synthesis of synechoxanthin (67) started from aryl iodide 62 by Suzuki-Miyaura cross coupling with mixed boronate 63. The resulting vinyl MIDA boronate moiety was transformed into the corresponding iodide 65 so that the same elongation process with building block 63 could be repeated again. The resulting polyenyl MIDA-boronate was activated as boronic ester 66 for the dimerisation step with dihalo alkene 64. In a remarkable recent paper the Burke group demonstrated that 12 different MIDA building blocks are in principal sufficient to iteratively prepare about 75% of all known polyene natural products. In that context organelles are chemical reactors which form a network with active mass transport among them. Microscopic compartmentation has been studied in plants to some degree.
21 For example, in Catharanthus roseus both intraand intercellular compartmentation play an important role in the biosynthesis of different types of terpenoid indole alkaloid skeletons such as vindoline 72, which is a precursor of the commercially important anticancer agents vinblastine and vincristine (Scheme 17).
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The early terpenoid precursors such as loganin 68 from the mevalonate terpenoid pathway are made in internal phloem parenchyma, the other important precursor tryptamine 70 in the epidermis. The last step of the terpenoid precursor secologanin 69 occurs in epidermis cells. Strictosidine synthase is present in the vacuoles and catalyzes the condensation of tryptamine 70 and secologanin 69 to yield the intermediate strictosidine 71. Finally, vindoline 72 is formed in other specialised cells, the ideoblasts and laticifers so that an intercellular transport of strictosidine must take place and the biosynthesis is compartmented. In essence, the ux through a pathway is controlled by transport from the site of production of a precursor to the site of the next enzyme.
The idea of compartmentation and passive transport is also found in synthetic chemistry at the interphase of two phases which can actively be promoted by phase transfer catalysts. E.g., this concept has been exploited for increasing the life time of free radicals using micelles as reactor compartments.
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Spatial separation can also be realised on a nanoscopic scale, where template structures based on e.g. multiple protein complexes are able to separate biosynthetic intermediates from each other. Such protein complexes are specically folded bringing various catalytic domains in close proximity thereby allowing bound biosynthetic intermediates to be processed by transfer to the next catalytic domain (Fig. 6) .
As mentioned above, erythromycin A (2) is a classical example of a complex antibiotic produced by Saccharopolyspora erythraea. Its type 1 polyketide synthase (PKS) is able to carry out 20 steps required to form the complex carbon backbone of 6-deoxythronolide (1) the advanced precursor of erythromycin A (2) (Schemes 1 and 21). This type 1 polyketide synthases represents an examples of molecular compartmentation. This megaenzyme complex is based on three large proteins that are composed of several enzymes and which can span several so called PKS modules. Altogether, the erythromycin PKS is organised in seven modules (one starting and six extender modules) (Scheme 18).
In each module acyl transferases (AT) choose a starting building block (propionyl-CoA) or six extender units (methylmalonyl-CoA), respectively, and transfer them to the individual acyl carrier proteins (ACP) that play a central role for the following transformations. The ACP-bound intermediates are handed over from one catalytic site to the next and from one module to the next. A set of enzymatic domains (e.g. KS, KR, DH, ER), each module is responsible for C2-homologation and functional group manipulations (keto / alcohol / alkene / alkane) (Fig. 7) .
This modular character and the permanent attachment of intermediates to the PKS lead to spatial separation of each chemical transformation. As the PKS operates continuously under steady state conditions all intermediates are only present in minute amounts (in theory one per protein).
Besides the ribosomal machinery, the PKS I assembly line is probably the most sophisticated megaenzyme architecture nature has developed. It is highly modular and in order to smoothly operate the interaction of neighbouring catalytic domains are perfectly orchestrated. Determining the dynamic architecture of the PKS type I is still difficult due to the large size and high complexity. Staunton and Leadlay developed a 'double-helical' model, that is based on the dimeric structure of subunits (Fig. 8) . 49 The model suggests that two identical proteins are wrapped against each other, which results in a lineup allowing all subunits to interact with one specic ACP domain. The underlying chemical concept of the PKS is compartmentation of single enzymatic steps and close spatial proximity that allow transfer of intermediates from one enzymatic domain to the next in a highly controlled manner (Fig. 8) .
The twisting peptide chain model also explains why the ACP and KS domains, which require a close proximity in order to allow condensation, are usually found at opposite ends of the peptide chain (Fig. 8, le-hand side) . It also explains how a seemingly single module can be used more than once, since a dimer could be used twice in theory, if the folding is favorable. Conceptually, the PKS multistep process resembles a domino reaction with the difference that stable and not high energy intermediates are transformed from one module to the next.
While the chemical approaches towards erythromycin A (2) relied on multistep batch processes (see Scheme 1) the biosynthesis of erythromycin A (2) is a continuous steady state process in which stable intermediates are passed from one spatial environment to the next and in each compartment (module) a new composition of enzymatic activities provides a choice for individual elongation chemistry. Clearly, this free choice does not exist for domino-type multistep transformations as discussed for terpene cyclases and their reactive intermediates.
Conceptually, there is a counterpart in synthetic chemistry. Multistep ow synthesis using linearly assembled ow devices resembles such a continuous compartmented process.
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Indeed, continuous ow processes are the best technical option to achieve spatial separation of individual transformations and the individual reactor may be regarded as an individual PKS module (Scheme 21 and Fig. 9 ). In continuously operated multistep ow synthesis the burden of work-up is minimised and isolation protocols ideally take place aer the last step. Furthermore, it is possible to set up ow systems in which two short linear synthetic ow sequences converge for allowing production of structurally complex products from two fragments. Technically, this concept is well established. E.g. one technical way to produce acrylic acid proceeds as a truly multistep continuous process. It starts with the steam cracking process of crude oil followed by a two step catalytic oxidation of propene via acrolein to acrylic acid. It is estimated that 5 to 10 6 tons of acrylic acid are produced worldwide much of it in continuously. 51 Commonly, intermediates formed in continuous ow processes are chemically stable enough so that other components can be added to the stream of the reaction mixture and conditions required for the next reaction can be adapted in the next reactor (Fig. 9) . These options make multistep ow processes more exible compared to multicomponent or cascade reactions.
A state-of-the-art multistep ow protocol was reported by the McQuade group in 2009. Their three-step ow synthesis of A second illustrative example, the continuous multistep ow synthesis of olanzapine (Zyprexa, 82), was recently reported by our own laboratories (Scheme 20). 53 A continuous three-step synthesis of thieno [1, 5] -benzodiazepine 80 started from aryl iodide 78 and thiophene 79 which were coupled via a Buchwald-Hartwig amination. The resulting intermediate 83 rst had to be passed through an in-line extractor for removing basederived ammonium salts then through a pad of silica that trapped palladium black before hydrogenation of the nitro group occurred in the second reactor. The aniline intermediate 84 that le this reactor was collected in a glass vessel where remaining hydrogen gas was liberated. At this point a stream of HCl in MeOH was added and the solution was injected into the tubular reactor that was heated inductively. As a result thieno [1, 5] -benzodiazepine 80 was collected aer 30 hours of continuous operation in 88% yield without the need of chromatographic purication. Finally, the synthesis of olanzapine 82 was achieved in 83% yield aer coupling with piperazine 81 using an inductively heated xed bed reactor containing a solid-phase bound titanium Lewis acid.
A most remarkable work was published earlier this year by Ley and coworkers. 54 During the total synthesis of the methyl ester of spirangien A (90, Scheme 21) a polyketide-based natural product isolated from myxobacteria Sorangium cellulosum So ce90 several polyketide fragments and hence the western part were synthesised under continuous multistep ow conditions without isolation of intermediates.
Strategically, intermediate 85 was transformed into the key building block 86. It contains a stereotriade that is found at C16-C18 and C26-C28, respectively, of spirangien A (89). Consequently, alkene 86 was transformed into the two advanced fragments 87 and 88. These were merged convergently by nucleophilic addition of the alkynyl lithium derivative derived from 87 to the aldehyde present in 88. At this point the authors switched from an overall ow process to the batch mode. The synthesis contains a lot of technical details and synthetic subtleties, so that only some key features of individual reactions and reaction sequences can be highlighted which demonstrate the state of the art of modern ow synthesis (Scheme 22).
Utilizing the technically simple device of a tube-in-tube reactor suitable for continuous reactions with gases, the Ley group conducted an asymmetric hydrogenation using Pfaltz's catalyst (R,R)-91 with alkene 85, which yielded hydrogenation product 92 in excellent yield and with good selectivity (Scheme 22). The catalyst's special feature is associated with the fact that it can be applied for the hydrogenation of non functionalised alkenes without the need of additional polar coordinating sites. 55 In the following, the protecting group was switched to an acetonide and all reagents and byproducts were removed from product 92 by pumping the reaction mixture through a cartridge of polymer supported benzylamine and basic alumina oxide. Finally, the resulting ester 93 was selectively reduced to yield the corresponding aldehyde which was followed by the experimentally challenging Roush crotylation with Z-but-2-enylboronate 94 to furnish fragment 86. It is noteworthy that aluminum containing byproducts were removed from the stream using a xed bed material composed of a polyalcohol immobilised on the polymer IRA-743. It is now possible to perform the Roush crotylation directly by addition of the boronate to the ow system. Control of stoichiometry was achieved by measuring the concentration of the resulting aldehyde using a FlowIR cell. Data processing, allowed automatic adjustment of the ow rate of the pump that is responsible for the addition of boronate 94.
It has to be stressed, that in several aspects this total synthesis is not biomimetic, although continuous processes and compartmentation were exploited. Ley's synthesis does not follow the linear logic of the polyketide synthase but has the exibility to dissect the spirangien A backbone into three major fragments which are merged in a convergent fashion, instead. 
Outlook
This conceptual review has examined the ideal multistep synthesis by analyzing nature. This article is not about biomimetic natural product synthesis but we rather suggest that the key to efficiency is steady state processing with intermediates that are immediately transformed to the next intermediate when formed until the target secondary metabolite is formed. We discussed four strategies (multicatalysis, domino reactions, iteration and compartmentation) that commonly proceed via short-lived intermediates. Nature, unlike chemists, uses these four strategies exibly, almost combinatorially like a juggler which is still a huge challenge for synthetic chemists. In essence, we believe that atom, step and redox-economy can only cover some major aspects of dening the ideal synthesis.
The exible use of these and additional strategies 21 should increase the efficiency of processes by minimizing work-up protocols of intermediates so that isolation of the nal product is the only purication issue.
We believe that harnessing and enhancing these strategies should not only be a priority for academia but also for industry. We envision that a combination of these methods may one day change 'traditional' synthetic chemistry and open up rapid access to a world of natural product-like compounds with astonishing complexity with only one or two purication steps (Scheme 23). We are aware that it is still a long way to go to develop such processes, but we believe we should not shy from such an opportunity to access a larger part of the chemical space in a more economical fashion.
Synthetic chemists can learn from nature by closely studying -not only individual transformations -but also how in vivo multistep processes are conducted. With the multitude of reactions discovered since Wöhler's rst preparation of urea in 1828, synthetic chemists have the potential to develop more powerful multistep processes than nature, if only we can manage to put them into use effectively.
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